Zethraeus N, Borgström F, Ström O, Kanis J A, Jönsson B
Centre for Health Economics, Stockholm School of Economics, P.O. Box 6501, S-113 83 Stockholm, Sweden.
Osteoporos Int. 2007 Jan;18(1):9-23. doi: 10.1007/s00198-006-0257-0. Epub 2006 Nov 9.
The purpose of the paper is to update and review the latest developments related to modelling and economic evaluation of osteoporosis in the period 2002-2005 and further to present a reference model for the assessment of the cost-effectiveness of the prevention and treatment of osteoporosis.
The reference model is intended to be used for fracture specific interventions affecting the risk of fracture. An interface version and an extensive description of the model is available on the internet ( http://www.healtheconomics.se ) and also accessible via the International Osteoporosis Foundation ( http://www.osteofound.org ). The purpose of the reference model is to improve the quality and comparability of cost-effectiveness analysis in the osteoporosis field and to serve as a tool for validation of present and future cost-effectiveness models. The reference model allows the cost-effectiveness analysis to be carried out from a societal perspective including intervention, morbidity and mortality costs. The model has been extensively tested and calibrated, and meets the properties of good decision analytic modelling. The model is a state transition Markov cohort model, which is characterised by a 50-year time horizon divided into one year cycle lengths. The following health states are included: "healthy", "hip fracture", "spine fracture", "wrist fracture", "other fracture", and "dead".
The model is flexible and allows for the estimation of the cost-effectiveness over different ranges for a selected number of variables (e.g., age, fracture risk, cost of intervention).
本文旨在更新和回顾2002 - 2005年期间与骨质疏松症建模和经济评估相关的最新进展,并进一步提出一个用于评估骨质疏松症预防和治疗成本效益的参考模型。
该参考模型旨在用于影响骨折风险的特定骨折干预措施。该模型的界面版本和详细描述可在互联网上获取(http://www.healtheconomics.se),也可通过国际骨质疏松症基金会获取(http://www.osteofound.org)。参考模型的目的是提高骨质疏松症领域成本效益分析的质量和可比性,并作为验证当前和未来成本效益模型的工具。该参考模型允许从社会角度进行成本效益分析,包括干预、发病率和死亡率成本。该模型已经过广泛测试和校准,符合良好决策分析建模的特性。该模型是一个状态转换马尔可夫队列模型,其特点是50年的时间跨度分为一年的周期长度。包括以下健康状态:“健康”、“髋部骨折”、“脊柱骨折”、“腕部骨折”、“其他骨折”和“死亡”。
该模型具有灵活性,允许针对选定的一些变量(例如年龄、骨折风险、干预成本)在不同范围内估计成本效益。